{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:17:31Z","timestamp":1792052251145,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.semarthrit.2025.152634","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T07:55:25Z","timestamp":1738137325000},"page":"152634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Use of biologic drug in the treatment of localized scleroderma and systemic sclerosis in children: A scoping review"],"prefix":"10.1016","volume":"71","author":[{"given":"Seher","family":"Sener","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1065-2363","authenticated-orcid":false,"given":"Ezgi Deniz","family":"Batu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semarthrit.2025.152634_bib0001","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00002281-200211000-00012","article-title":"Scleroderma in children","volume":"14","author":"Foeldvari","year":"2002","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152634_bib0002","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.clindermatol.2006.07.004","article-title":"Systemic and localized scleroderma","volume":"24","author":"Chung","year":"2006","journal-title":"Clin Dermatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152634_bib0003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.rdc.2007.11.004","article-title":"Systemic sclerosis and localized scleroderma in childhood","volume":"34","author":"Zulian","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152634_bib0004","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1590\/abd1806-4841.20152890","article-title":"Localized scleroderma: clinical spectrum and therapeutic update","volume":"90","author":"Careta","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152634_bib0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1586\/edm.11.26","article-title":"Diagnosis and treatment of systemic and localized scleroderma","volume":"6","author":"Khanna","year":"2011","journal-title":"Expert Rev Dermatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152634_bib0006","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2018-214697","article-title":"Consensus-based recommendations for the management of juvenile localised scleroderma","volume":"78","author":"Zulian","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152634_bib0007","first-page":"961","article-title":"Systemic sclerosis\/scleroderma: a treatable multisystem disease","volume":"78","author":"Hinchcliff","year":"2008","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.semarthrit.2025.152634_bib0008","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-3-030-80699-6_13","article-title":"Scleroderma","author":"Wiesendanger","year":"2022","journal-title":"Rheumatol Primary Care Providers: Clin Casebook"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152634_bib0009","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/medicina59020247","article-title":"Impact of innovative treatment using biological drugs for the modulation of diffuse cutaneous systemic sclerosis: a systematic review","volume":"59","author":"Fern\u00e1ndez-L\u00e1zaro","year":"2023","journal-title":"Medicina"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152634_bib0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12016-020-08831-4","article-title":"Clinical treatment options in scleroderma: recommendations and comprehensive review","volume":"62","author":"Zhao","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152634_bib0011","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3390\/ph16081066","article-title":"Novel therapeutic strategies in the treatment of systemic sclerosis","volume":"16","author":"Gumkowska-Sroka","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152634_bib0012","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152634_bib0013","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3899\/jrheum.100361","article-title":"Biologic therapy for systemic sclerosis: a systematic review","volume":"38","author":"Phumethum","year":"2011","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152634_bib0014","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40272-019-00363-5","article-title":"Update on the systemic treatment of pediatric localized scleroderma","volume":"21","author":"Foeldvari","year":"2019","journal-title":"Pediatr Drugs"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152634_bib0015","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1093\/rheumatology\/keaa193","article-title":"Rituximab for rapidly progressive juvenile systemic sclerosis","volume":"59","author":"Zulian","year":"2020","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152634_bib0016","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/rheumatology\/kex382","article-title":"Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma","volume":"57","author":"Lythgoe","year":"2018","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152634_bib0017","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.semarthrit.2020.03.020","article-title":"Abatacept in the treatment of localized scleroderma: a pediatric case series and systematic literature review","volume":"50","author":"Kalampokis","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152634_bib0018","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152634_bib0019","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jamadermatol.2018.5040","article-title":"A case of pansclerotic morphea treated with Tocilizumab","volume":"155","author":"Zhang","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152634_bib0020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/37.2.222","article-title":"Atypical juvenile generalized scleroderma presenting as polyarthritis and failure to thrive","volume":"37","author":"Wulffraat","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152634_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656407","article-title":"Case report: pansclerotic morphea-clinical features, differential diagnoses and modern treatment concepts","volume":"12","author":"Vent\u00e9jou","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152634_bib0022","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/pde.15485","article-title":"Novel multispectral imaging to predict disease progression in pediatric morphea","volume":"41","author":"O'Connor","year":"2024","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152634_bib0023","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10072-019-04187-6","article-title":"Anti-GAD epileptic encephalopathy in a toddler with Parry-Romberg syndrome","volume":"41","author":"Sotgiu","year":"2020","journal-title":"Neurol Sci"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152634_bib0024","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00296-019-04269-w","article-title":"Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review","volume":"39","author":"Soh","year":"2019","journal-title":"Rheumatol Int"},{"issue":"5 Pt 1","key":"10.1016\/j.semarthrit.2025.152634_bib0025","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.reuma.2018.05.001","article-title":"en coup de sabre\" with epilepsy and uveitis successfully treated with Tocilizumab","volume":"16","author":"Osminina","year":"2020","journal-title":"Reumatol Clin"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152634_bib0026","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/pde.12279","article-title":"Pansclerotic morphea with features of eosinophilic fasciitis: distinct entities or part of a continuum?","volume":"31","author":"Odhav","year":"2014","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152634_bib0027","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/2397198320975872","article-title":"Parry Romberg disease with En Coup de Sabre Scleroderma: effect of tocilizumab on periodontal bone inflammation","volume":"6","author":"Meneghetti","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152634_bib0028","first-page":"211","article-title":"Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?","volume":"35","author":"Martini","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152634_bib0029","doi-asserted-by":"crossref","first-page":"R188","DOI":"10.1186\/ar4378","article-title":"Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma","volume":"15","author":"Magee","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152634_bib0030","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1093\/rheumatology\/keaa873","article-title":"Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152634_bib0031","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5301\/jsrd.5000259","article-title":"Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients","volume":"2","author":"Foeldvari","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2025.152634_bib0032","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/18743129014090100030","article-title":"A case report of successful treatment of recalcitrant childhood localized scleroderma with Infliximab and Leflunomide","volume":"9","author":"Ferguson","year":"2015","journal-title":"Open Rheumatol J"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152634_bib0033","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1007\/s10067-023-06677-7","article-title":"Remission rates and risk factors for relapse in pediatric morphea: a multicenter retrospective study of Pediatric Rheumatology Academy (PeRA)-Research Group (RG)","volume":"42","author":"Ba\u011flan","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152634_bib0034","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3390\/diagnostics13122103","article-title":"Pulmonary nodules in juvenile systemic sclerosis: a case-series from the National Registry for Childhood onset scleroderma (NRCOS)","volume":"13","author":"Li","year":"2023","journal-title":"Diagnostics"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152634_bib0035","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1093\/rheumatology\/keac103","article-title":"Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications","volume":"61","author":"Heshin-Bekenstein","year":"2022","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152634_bib0036","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1093\/rheumatology\/keab738","article-title":"Systemic sclerosis sine scleroderma in children","volume":"61","author":"Zulian","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2025.152634_bib0037","doi-asserted-by":"crossref","unstructured":"Stevens B.E., Torok K.S., Li S.C., et al. Clinical characteristics and factors associated with disability and impaired quality of life in children with juvenile systemic sclerosis: results from the childhood arthritis and Rheumatology Research Alliance legacy registry. Arthritis Care Res 2018;70(12):1806\u201313.","DOI":"10.1002\/acr.23547"},{"issue":"20","key":"10.1016\/j.semarthrit.2025.152634_bib0038","doi-asserted-by":"crossref","first-page":"7767","DOI":"10.3390\/ijms21207767","article-title":"Biological and clinical changes in a pediatric series treated with off-label JAK inhibitors","volume":"21","author":"Pin","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152634_bib0039","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/annrheumdis-2017-212454","article-title":"Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk","volume":"77","author":"Moreno-Moral","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152634_bib0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/03009742.2021.1881154","article-title":"Too young to fail: a case report on the effectiveness of tocilizumab for paediatric systemic sclerosis-associated interstitial lung disease","volume":"50","author":"Maniscalco","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152634_bib0041","doi-asserted-by":"crossref","DOI":"10.1177\/11795441211066307","article-title":"Problems to consider before determining the regimen of the treatment for juvenile systemic sclerosis treatment: a case report where Tocilizumab monotherapy succeeded efficiently and safely","volume":"15","author":"Funauchi","year":"2022","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152634_bib0042","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/rheumatology\/keaa208","article-title":"Early detection of ventricular dysfunction in juvenile systemic sclerosis by speckle tracking echocardiography","volume":"60","author":"Civieri","year":"2021","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152634_bib0043","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00296-020-04732-z","article-title":"Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study","volume":"41","author":"Adrovic","year":"2021","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152634_bib0044","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5606\/ArchRheumatol.2018.6578","article-title":"Juvenile scleroderma: a referral center experience","volume":"33","author":"Adrovic","year":"2018","journal-title":"Arch Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152634_bib0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12519-019-00320-9","article-title":"Overview of juvenile localized scleroderma and its management","volume":"16","author":"Li","year":"2020","journal-title":"World J Pediatr"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152634_bib0046","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11926-020-00910-x","article-title":"Treatment in juvenile scleroderma","volume":"22","author":"Zulian","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152634_bib0047","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2340\/00015555-2878","article-title":"Abatacept improves skin-score and reduces lesions in patients with localized scleroderma: a case series","volume":"98","author":"Fage","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.semarthrit.2025.152634_bib0048","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2022.09.024","article-title":"Tocilizumab for refractory morphea in adults: a case series","volume":"30","author":"Lonowski","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152634_bib0049","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2665-9913(22)00131-X","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"4","author":"Ebata","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152634_bib0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.berh.2019.01.011","article-title":"Outcomes of patients with systemic sclerosis treated with tocilizumab: case series and review of the literature","volume":"32","author":"Zacay","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152634_bib0051","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T14:52:07Z","timestamp":1741099927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225000058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":51,"alternative-id":["S0049017225000058"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152634","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of biologic drug in the treatment of localized scleroderma and systemic sclerosis in children: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152634"}}